Baseline and procedure variables between SR alone first-line and SR+CA first-line groups
| Baseline and procedure variables | SR alone first-line (n=1069) | SR+CA first-line (n=164) | P value |
| Age, years, median (IQR） | 65 (55–73) | 69 (58–77) | 0.007 |
| Male sex, n (%) | 684 (64.0) | 97 (59.2) | 0.231 |
| Transport mode, n (%) | 0.846 | ||
| Mothership | 676 (63.2) | 105 (64.0) | |
| Transfer | 393 (36.8) | 59 (36.0) | |
| Hypertension, n (%) | 606 (56.7) | 88 (53.7) | 0.466 |
| Diabetes mellitus, n (%) | 184 (17.2) | 30 (18.3) | 0.734 |
| Hyperlipidaemia, n (%) | 94 (8.8) | 15 (9.2) | 0.882 |
| Coronary heart disease, n (%) | 166 (15.5) | 26 (15.9) | 0.915 |
| Atrial fibrillation, n (%) | 364 (34.1) | 76 (46.3) | 0.002 |
| Prior stroke, n (%) | 221 (20.7) | 44 (26.8) | 0.074 |
| Smoking history, n (%) | 0.242 | ||
| Never smoking | 666 (62.3) | 93 (56.7) | |
| Previous smoking | 72 (6.7) | 16 (9.8) | |
| Current smoking | 331 (31.0) | 55 (33.5) | |
| SBP, mm Hg | 145 (130–160) | 145 (130–158) | 0.187 |
| Admission NIHSS* | 17 (12–22) | 16 (12–21) | 0.123 |
| Admission ASPECTS† | 9 (7–10) | 9 (7–10) | 0.490 |
| Blood glucose, mmol/L, median (IQR） | 7.1 (6.0–8.8) | 6.9 (5.8–7.7) | 0.063 |
| Antiplatelets before EVT, n (%) | 161 (15.1) | 23 (14.0) | 0.729 |
| Anticoagulants before EVT, n (%) | 50 (4.7) | 6 (3.7) | 0.560 |
| Pretreatment with IVT, n (%) | 280 (26.2) | 55 (33.5) | 0.049 |
| Occlusion site, n (%) | 0.663 | ||
| ICA | 256 (24.0) | 38 (23.2) | |
| M1 | 496 (46.4) | 84 (51.2) | |
| M2 | 100 (9.4) | 14 (8.5) | |
| Vertebrobasilar artery | 217 (20.3) | 28 (17.1) | |
| Tandem occlusion, n (%) | 157 (14.7) | 12 (7.3) | 0.011 |
| Underlying ICAD, n (%) | 0.404 | ||
| Yes | 313 (29.3) | 40 (24.4) | |
| No | 644 (60.2) | 104 (63.4) | |
| Undetermined | 112 (10.5) | 20 (12.2) | |
| Stroke subtype by TOAST criteria, n (%) | 0.062 | ||
| Large artery atherosclerosis | 496 (46.4) | 65 (39.6) | |
| Cardioembolism | 394 (36.9) | 76 (46.3) | |
| Other or unknown aetiology | 128 (12.0) | 13 (7.9) | |
| Undetermined | 51 (4.8) | 10 (6.1) | |
| General anaesthesia, n (%) | 440 (41.2) | 44 (26.8) | 0.001 |
| GP IIb/IIIa receptor inhibitor, n (%) | 559 (52.3) | 81 (49.4) | 0.489 |
| Heparin during the procedure, n (%) | 546 (51.1) | 66 (40.2) | 0.010 |
| OTP, min, median (IQR)‡ | 300 (215–440) | 295 (225–415) | 0.950 |
Bold values indicate statistical significance
*Six missing data.
†Eight missing data.
‡Ten missing data.
ASPECTS, Alberta Stroke Program Early CT Score; CA, contact aspiration; EVT, endovascular thrombectomy; GP, glycoprotein; ICA, intracranial cerebral artery; ICAD, intracranial atherosclerotic disease; IVT, intravenous thrombolysis; M1, middle cerebral artery M1 segment; M2, middle cerebral artery M2 segment; NIHSS, National Institutes of Health Stroke Scale; OTP, onset-to-puncture time; SBP, systolic blood pressure; SR, stent retriever; TOAST, Trial of ORG 10172 in Acute Stroke Treatment criteria.